Opinion|Videos|June 27, 2024
Strategies to Increase Biomarker Testing Rates
Key opinion leaders provide insight to providing biomarker testing within and beyond guideline recommendations.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What strategies can help ensure all appropriate mNSCLC patients receive comprehensive biomarker testing in line with guidelines?
- What are community-based best practices, and what are academic-based practices?
- Despite the guidelines, what gaps exist between recommended biomarker testing rates and real-world testing utilization?
Advertisement
Related to this article
Leaders from Boehringer Ingelheim, Incyte, Pfizer, and Takeda told the audience at Patient-Centered Oncology Care® that artificial intelligence (AI) is compressing discovery timelines, but that gaps in testing, data, and community access still decide which patients benefit.
Many patients who stop a GLP-1 RA regain weight. How plans can measure adherence when cash-pay fills go unseen.
Invivyd presented preclinical IDWeek 2026 data on VMS063, an investigational antibody that neutralized B3 and D8 measles variants in vitro.
In more than 250,000 adults with prediabetes and obesity, GLP-1 users had lower risks of type 2 diabetes, death, and cardiovascular events.
Sphingolipid profiles in plasma and breath condensate differed between IPF and f-HP and tracked with disease severity, CHEST 2026 data show.
The FDA granted accelerated approval to the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis (RRP).
In nearly 443,000 US adults, both low-frequency and heavy cannabis use were linked to higher odds of cardiovascular disease, led by stroke.
Clinicians separate idiopathic hypersomnia from depression-related sleepiness and interpret real-world and trial data for better outcomes.
Advertisement
Advertisement
Trending on AJMC
1
Enlicitide LDL-C Lowering Holds Across Risk Levels Up to 2 Years
2
Occasional Cannabis Use Linked to 40% Higher Odds of Stroke
3
As Employers Pull Back on GLP-1s, Andel and Novo Offer a Workaround
4
FDA Approves First Plasmid DNA-Based Immunotherapy for Adults With RRP
5